Fingolimod Capsule
Product Images NDC 60505-4332

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Fingolimod (NDC 60505-4332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Btl-lbl (Btl Lbl)

Btl-lbl (Btl Lbl)
Fingolimod Capsules 0.5 mg oral capsules packaging label by Apotex Corp. The label shows 30 capsules per bottle, with each capsule containing 0.5 mg of fingolimod (equivalent to 0.56 mg fingolimod hydrochloride). It includes storage instructions and a note to dispense the enclosed medication guide. Manufactured by MSN Laboratories Private Limited and labeled for Apotex Corp., Woston, Florida.*
FDA Label Image

Ctn-lbl (Ctn Lbl)

Ctn-lbl (Ctn Lbl)
Fingolimod Capsules 0.5 mg oral capsules packaging label from Apotex Corp. The label indicates 28 (2 x 14) unit-dose capsules per package, equivalent to 0.56 mg fingolimod hydrochloride, with storage instructions and manufacturing information. The label includes the NDC 60505-4332-1 and emphasizes dispensing with the enclosed Medication Guide.*
FDA Label Image

Fingolimod Chemical Structure (Fingo 01)

Fingolimod Chemical Structure (Fingo 01)
Chemical structure diagram of Fingolimod, showing its molecular components including a phenyl ring, a long alkyl chain, and functional groups with hydroxyl and ammonium chloride moieties.*
FDA Label Image

Figure 1 Time To 3-month Confirmed Disability Progression – Study 1 (itt Population) (Fingo 02)

Figure 1  Time To 3-month Confirmed Disability Progression – Study 1 (itt Population) (Fingo 02)
A line graph showing the percentage of patients with three-month confirmed progression over time in days, comparing Fingolimod Capsules 0.5 mg (red solid line) and Placebo (black dashed line). The graph tracks increases up to about 630 days, with Placebo reaching approximately 24% and Fingolimod about 18% by the end.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.